These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 7694894)

  • 1. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b.
    Saracco G; Rosina F; Abate ML; Chiandussi L; Gallo V; Cerutti E; Di Napoli A; Solinas A; Deplano A; Tocco A
    Hepatology; 1993 Dec; 18(6):1300-5. PubMed ID: 7694894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus markers in patients with long-term biochemical and histological remission of chronic hepatitis.
    Saracco G; Abate ML; Baldi M; Calvo PL; Manzini P; Brunetto MR; Oliveri F; Kuo G; Chien D; Houghton M
    Liver; 1994 Apr; 14(2):65-70. PubMed ID: 7515141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C.
    Lampertico P; Rumi M; Romeo R; Craxì A; Soffredini R; Biassoni D; Colombo M
    Hepatology; 1994 Jan; 19(1):19-22. PubMed ID: 7506225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks.
    Reichard O; Foberg U; Frydén A; Mattsson L; Norkrans G; Sönnerborg A; Wejstål R; Yun ZB; Weiland O
    Hepatology; 1994 Feb; 19(2):280-5. PubMed ID: 7507462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon.
    Castillo I; Bartolomé J; Navas S; Gonzalez S; Herrero M; Carreño V
    Hepatology; 1994 Jun; 19(6):1342-6. PubMed ID: 8188165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
    Olaso V; Córdoba J; Berenguer M; Prieto M; Lainez B; Argüello L; Valverde J; Pascual S; Gobernado M; Berenguer J
    Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of antibodies to hepatitis C virus during interferon-alpha therapy.
    Yuki N; Hayashi N; Hagiwara H; Takehara T; Katayama K; Kasahara A; Fusamoto H; Kamada T
    Hepatology; 1993 Jun; 17(6):960-5. PubMed ID: 7685734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody pattern's lack of predictivity in determining the response of viral hepatitis C to interferon therapy.
    Berardo C; Gerardi R; Delle Monache M; Del Vecchio S; Ricci GL
    Ital J Gastroenterol; 1994; 26(8):398-400. PubMed ID: 7535599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in antibody titers to hepatitis C virus following interferon therapy for chronic infection.
    Urushihara A; Sodeyama T; Matsumoto A; Tanaka E
    J Med Virol; 1994 Apr; 42(4):348-56. PubMed ID: 7519250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial.
    Diodati G; Bonetti P; Noventa F; Casarin C; Rugge M; Scaccabarozzi S; Tagger A; Pollice L; Tremolada F; Davite C
    Hepatology; 1994 Jan; 19(1):1-5. PubMed ID: 7506223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group.
    Lindsay KL; Davis GL; Schiff ER; Bodenheimer HC; Balart LA; Dienstag JL; Perrillo RP; Tamburro CH; Goff JS; Everson GT; Silva M; Katkov WN; Goodman Z; Lau JY; Maertens G; Gogate J; Sanghvi B; Albrecht J
    Hepatology; 1996 Nov; 24(5):1034-40. PubMed ID: 8903371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group.
    Poynard T; Bedossa P; Chevallier M; Mathurin P; Lemonnier C; Trepo C; Couzigou P; Payen JL; Sajus M; Costa JM
    N Engl J Med; 1995 Jun; 332(22):1457-62. PubMed ID: 7739681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term prognosis of chronic hepatitis C after treatment with interferon alpha 2b and characterization of incomplete responders.
    Hakozaki Y; Shirahama T; Katou M; Nakagawa K; Oba K; Yoshii O; Matsumoto T; Kuwabara N; Mitamura K
    Am J Gastroenterol; 1996 Oct; 91(10):2144-9. PubMed ID: 8855738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis.
    Magrin S; Craxì A; Fabiano C; Fiorentino G; Marino L; Almasio P; Pinzello GB; Palazzo U; Vitale M; Maggio A
    J Med Virol; 1992 Nov; 38(3):200-6. PubMed ID: 1283753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies.
    Schvarcz R; Weiland O; Wejstål R; Norkrans G; Frydén A; Foberg U
    Scand J Infect Dis; 1989; 21(6):617-25. PubMed ID: 2482536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha-Interferon retreatment of patients with chronic hepatitis C.
    Rabinovitz M; Block G; Finkelstein SD
    Am J Gastroenterol; 1996 Aug; 91(8):1523-6. PubMed ID: 8759654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in antibodies to specific hepatitis C virus antigens with interferon-alpha therapy: analysis by recombinant immunoblot assay.
    Yuki N; Hayashi N; Hagiwara H; Takehara T; Katayama K; Kasahara A; Fusamoto H; Kamada T
    Am J Gastroenterol; 1993 Jun; 88(6):914-8. PubMed ID: 7684885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.
    Shiffman ML; Hofmann CM; Thompson EB; Ferreira-Gonzalez A; Contos MJ; Koshy A; Luketic VA; Sanyal AJ; Mills AS; Garrett CT
    Hepatology; 1997 Sep; 26(3):780-5. PubMed ID: 9303513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.